Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
about
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
description
clinical trial
@en
klinisch onderzoek
@nl
name
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
@en
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
@nl
type
label
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
@en
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
@nl
prefLabel
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
@en
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
@nl
P1476
Open-Label, to Evaluate the Ef ...... iitis (EGPA) Study: RITE Study
@en
P1813
RITE
@en
P3098
NCT02947945
P580
2017-09-12T00:00:00Z
P582
2018-12-01T00:00:00Z